Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Sputnik Light is the first component of Sputnik V
Sputnik Light can become a major booster for those vaccinated with inactivated Chinese Covid-19 vaccines globally after China has officially recommended mix & match approach with adenoviral vector-based vaccines as boosters
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
_256_384.jpg){kind=logo}
Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad
This is the ninth Covid-19 vaccine approved in India
The recommendations have been sent to the Drugs Controller General of India (DCGI) for the final approval
The company has started manufacturing the Sputnik Light vaccine
Subscribe To Our Newsletter & Stay Updated
